Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets, Operating Loss Carryforwards
Deferred Tax Assets, Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets, operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets, operating loss carryforwards?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets, operating loss carryforwards of $41.46M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets, operating loss carryforwards changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets, operating loss carryforwards increased by 23.1% year-over-year, from $33.68M to $41.46M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets, operating loss carryforwards?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets, operating loss carryforwards has grown at a 50.4% compound annual growth rate (CAGR), from $5.39M to $41.46M.